KL-6/MUC-1 sebagai Penanda Penyakit Paru Interstisial
DOI:
https://doi.org/10.55175/cdk.v45i1.845Keywords:
Penyakit paru interstitial, Krebs Von De Lungen-6 (KL-6), marker potensialAbstract
Penyakit paru interstisial ditandai dengan inflamasi dan fibrosis interstitium paru, yang merupakan kerusakan dan/atau regenerasi pneumosit tipe II. Diagnosisnya membutuhkan HRCT (high resolution computed tomography), bronkoskopi, dan/atau biopsi paru yang cukup invasif. Krebs Von De Lungen-6 (KL-6), glikoprotein musinous dengan berat molekul 200 kD, yang disekresi oleh pneumosit tipe II dan sel-sel epitel bronkiolar sangat menjanjikan untuk dijadikan marker yang potensial dan kurang invasif bagi kelainan paru interstitial ini.
Interstitial lung diseases are marked by inflammation and fibrosis in the interstitium, a damage and/or regeneration of type II pneumocytes. HCRT (high resolution computed tomography), bronchoscopy, and/or invasive lung biopsy are needed for diagnosis. Krebs Von De Lungen-6 (KL-6), a mucinous, 200 kD molecule weight glycoproteins, secreted by a type II pneumocytes and bronchiolar epithel cells is very promising as a potential and less invasive marker for this interstitial lung diseases.
Downloads
References
Ishikawaa N, Hattoria N, Yokoyamab A, Kohnoa N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respiratory Investigation Elsevier. 2012;50:3-13.
Torrens D, Iwata R. Serum biomarker for lung disease. Medical Laboratory Observer [Internet]. 2012. Available from: https://www.sekisuidiagnostics.com/writable/resources/files/serum_biomarkers.pdf
Bonella F, Ohshimo S, Miaotian C, Griese M, Guzman J, Costabel U. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2013;8:1-10.
Tzouvelekis A, Gkouliatsis G, Anevlavis S, Bouros D. Serum biomarkers in interstitial lung diseases. Respir Res. 2005;6:1-24.
Ogihara T, Hirano K, Morinobu T, Kim H, Ogawa S, Hiroi M, et al. Plasma KL-6 predicts the development and outcome of bronchopulmonary dysplasia. Pediatr Res. 2006;60:613-8.
Hisata S, Kimura Y, Shibata N, Ono S, Kobayashi T, Chiba S. A normal range of KL-6/MUC1 independent of elevated SP-D indicates a better prognosis in the patients with honeycombing on high-resolution computed tomography. Pulm Med. 2011;2011:806014.
Kondo T, Hattori N, Ishikawa N, Murai H, Haruta Y, Hirohashi N, et al. KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrom. Respiratory Res. 2011;12:1-7.
Ohshimo S, Bonella F, Grammann N, Starke K, Cui A, BauerPC, et al. Serum KL-6 as a novel disease marker in adolescent and adult cystic fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2009;26:47-53.
Siawaya JFD, Beyers N, Helden P, Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. Clin Experiment Immunol. 2009;156: 69–77.
Gassas A, Schechter T, Krueger J, Barnes HC, Sung L, Ali M, et al. Serum Krebs Von Den Lungen-6 as a biomarker for early detection of bronchiolitis obliterans syndrome in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1524-31.
Kawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K, Furonaka O, et al. Change in serum Kl-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respiratory Res. 2011;12:1-11.
Miwa S, Suzuki Y, Shirai M, Ohba H, Kanai M, Eifuku T, et al. Assessment of serum Kl-6 as a prognostic marker in pulmonary tuberculosis patients. Int J Tuberc Lung Dis. 2012;17:240-2.
Siawaya JFD, Chegou NN, Heuvel MM, Diacon AH, Beyers N, Helden P, et al. Differential cytokine/chemokines and Kl-6 profiles in patients with different forms of tuberculosis. Cytokine 2009;47:132–6.
Fathi M, Helmers SB, Lundberg IE. KL-6: A serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med. 2012;271:589–97.
Kida Y, Ohshimo S, Ota K, Tamura T, Otani T, Une K, et al. KL-6, a human MUC1 mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome. Orphanet J Rare Dis. 2012;7:1-8.
Determann RM, Royakkers AANM, Haitsma JJ, ZhangH, Slutsky AS, RanieriVM, et al. Plasma levels of surfactant protein D and Kl-6 for evaluation of lung injury in critically ill mechanically ventilated patients. BMC Pulmonary Med. 2010;10:1-9
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
